Inhibitor/Activator
| Cat.No. | Name | Information |
|---|---|---|
| M7224 | RS 504393 | RS 504393 is a highly selective CCR2 chemokine receptor antagonist, with IC50 values of 89 nM and > 100 μM for inhibition of human recombinant CCR2 and CCR1 receptors, respectively. |
| M1971 | Maraviroc | Maraviroc (UK-427857) is a selective CCR5 antagonist with potent anti-human immunodeficiency virus type 1 (HIV-1) activity and favorable pharmacological properties. |
| M28023 | GSK2239633A | GSK2239633A is a CC-chemokine receptor 4 (CCR4) antagonist, which inhibits the binding of [125I]-TARC to human CCR4 with a pIC50 of 7.96 ± 0.11. |
| M27990 | CCR2 antagonist 5 | CCR2 antagonist 5 is a selective, orally active hCCR2 inhibitor with good binding affinity (IC50=37 nM) and potent functional antagonism (chemotaxis IC50=30 nM). CCR2 antagonist 5 displays a Ki of 9.6 µM for mCCR2 binding. CCR2 antagonist 5 can be used in the research of inflammatory disease. |
| M27929 | BMS-817399 | BMS-817399 is a potent, selective, and orally bioavailable CCR1 antagonist. BMS-817399 exhibits CCR1 binding affinity and chemotaxis inhibition potencies of 1 and 6 nM (IC50), respectively. BMS-817399 can be used for the research of rheumatoid arthritis. |
| M27628 | CCX354 | CCX354 is an antagonist of CCR1, with anti-inflammatory activity. |
| M25595 | PF-07054894 | |
| M25287 | Carlumab | Carlumab (CNTO 888) is a humanised anti-CCL2 (chemokine ligand 2) antibody with high affinity. Carlumab can be used in cancer research, particularly in prostate cancer. |
| M25245 | Leronlimab | Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer. |
| M25221 | Bertilimumab | Bertilimumab (CAT 213; iCo-008) is a human monoclonal antibody targeting eotaxin-1 (CCL11). Bertilimumab has the potential for allergic disorders research. |
| M21145 | BMS-753426 | BMS-753426 is an orally effective CCR2 antagonist. |
| M20822 | (Rac)-PF-4136309 | (Rac)-PF-4136309 is an isoform of PF-4136309. PF-4136309 (INCB8761, PF-04136309) is a potent, selective, and orally bioavailable CCR2 antagonist with an IC50 of 5.2 nM for human CCR2. |
| M20618 | ZK756326 2HCl | ZK756326 is a full agonist of CCR8（Chemokine receptor 8） with an IC50 of 1.8 μM, dose-responsively eliciting an increase in intracellular calcium and cross-desensitizing the response of the receptor to CCL1. |
| M13930 | Vercirnon sodium | Vercirnon (GSK1605786A) sodium is an orally bioavailable, selective, and potent antagonist of CCR9. |
| M13929 | Vercirnon | Vercirnon (GSK1605786A) is an orally bioavailable, selective, and potent antagonist of CCR9. |
| M13927 | TAK-220 | TAK-220 is a selective and orally bioavailable CCR5 antagonist, with IC50s of 3.5 nM and 1.4 nM for inhibition on the binding of RANTES and MIP-1α to CCR5, respectively, but shows no effect on the binding to CCR1, CCR2b, CCR3, CCR4, or CCR7; TAK-220 also selectively inhibits HIV-1, with EC50s of 1.2 nM (HIV-1 KK), 0.72 nM (HIV-1 CTV), 1.7 nM (HIV-1 HKW), 1.7 nM (HIV-1 HNK), 0.93 nM (HIV-1 HTN), and 0.55 nM (HIV-1 HHA). |
| M13925 | GW 766994 | GW 766994 (GW 994) is an orally active and specific chemokine receptor-3 (CCR3) antagonist. GW 766994 has the potential for asthma and eosinophilic bronchitis research. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
